Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Keerbergen – page 59

1 980 clinical trials in Keerbergen, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Keerbergen at a glance
1 980
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 980 trials in Keerbergen

Open in trial search

Study on the Safety and Effectiveness of VB10.16 and Pembrolizumab for Patients with HPV16-Positive Head and Neck Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Nykode Therapeutics ASA

Study Comparing 177Lu-Edotreotide and Everolimus for Patients with Neuroendocrine Tumors in the Lung and Thymus

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Grupo Espanol De Tumores Neuroendocrinos

Study on [68Ga]Ga-PentixaFor PET Imaging for Better Risk and Disease Assessment in Patients with Multiple Myeloma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Gallium (68GA)
  • Sponsor:University Of Antwerp

Phase III Trial Comparing ABVD vs A2VD Treatment With PET-Guided Radiation Therapy for Patients With Early Stage Hodgkin Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin
  • Sponsor:University College London

Study of Tebentafusp and Pembrolizumab for Patients with Previously Treated Advanced Melanoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Immunocore Limited

Study on the Effectiveness of Clofazimine and Drug Combination for Treating Mycobacterium abscessus Lung Disease in Adult Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin
  • Sponsor:The University Of Queensland

Breast cancer

Recruiting

Study on the Effectiveness of Inavolisib with Trastuzumab and Pertuzumab for Patients with HER2-Positive, HR-Positive, PIK3CA Mutant Early Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Inavolisib
  • Sponsor:GBG Forschungs GmbH

Migraine+2

Recruiting

Study on the Safety and Effectiveness of Atogepant for Preventing Episodic Migraine in Children and Teens Aged 6 to 17

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effects of Carboplatin and Cisplatin in Patients with Early-Stage, Intermediate-Risk Cervical Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:CEEGOG z.s.

Vulval cancer

Recruiting

Study Comparing Chemoradiation and Chemotherapy with Cisplatin, Paclitaxel, and Carboplatin for Patients with Advanced Vulvar Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Long-Term Follow-Up Study for Patients Treated with Idecabtagene Vicleucel or Lisocabtagene Maraleucel for Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BMS-986515
  • Sponsor:Celgene Corp.

Migraine+2

Recruiting

Study on Long-term Safety and Tolerability of Atogepant for Children and Teens (Ages 6-17) with Migraine

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Keerbergen

What the registry says about research in the country

01 Gastroenterology Research

Clinical investigations focusing on proton pump inhibitor (PPI) de-prescribing strategies in primary care settings. The research examines alternative approaches for patients with chronic PPI use who lack clear long-term usage indications.

  • Functional Dyspepsia Management
  • Gastroesophageal Reflux Treatment
  • Heartburn Control Strategies

This innovative study evaluates the effectiveness of on-demand PPI use and alginate formulation therapy compared to traditional gradual dose reduction methods.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.